Consistently delivered good results. Least PE among Healthcare stocks. PEG < 1 Good ICR , Low debt ROE, ROCE better than industry compatriots Excellent Sales and profit growth
Expecting breakout if good to great results
Note
Excellent Results Mar 2024 NSE:NH QOQ 👉Revenue rose 6.23% to 1279cr 👉Profit rose 1.60% to 191cr 👉EPS rose 1.41% to 9.33 👉EBITDA rose 5.73% to 295 👉EBITDA Margin drops 0.00% BPS to 23% YOY 👉Revenue rose 4.66% from 1222cr 👉Profit rose 10.40% from 173cr 👉EPS rose 10.15% from 8.47 👉EBITDA rose 6.88% from 276 👉EBITDA Margin drops 0.00% BPS from 23% Fundamentals 👉Stock Price is 1296.3( as of 3/31/2024) 👉Stock PE is 33.57 👉Stock EPS is 38.62 👉Dividend Announced of Rs.4 Growth 👉2 Year Revenue CAGR is 16.48% 👉2 Year Profit CAGR is 51.98% 👉2 Year EPS CAGR is 51.94% 👉2 Year Price CAGR is 31.46%"""
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.